SELLAS Life Sciences Group, Inc.

DB:RXK3 Stock Report

Market Cap: €69.1m

SELLAS Life Sciences Group Future Growth

Future criteria checks 0/6

SELLAS Life Sciences Group is forecast to grow earnings and revenue by 42.3% and 69% per annum respectively while EPS is expected to grow by 51% per annum.

Key information

42.3%

Earnings growth rate

51.0%

EPS growth rate

Biotechs earnings growth36.5%
Revenue growth rate69.0%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:RXK3 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202616-36N/AN/A2
12/31/2025N/A-36N/AN/A2
12/31/2024N/A-34N/AN/A2
6/30/2024N/A-34-35-32N/A
3/31/2024N/A-36-36-30N/A
12/31/2023N/A-37-37-31N/A
9/30/2023N/A-38-37-32N/A
6/30/2023N/A-36-33-31N/A
3/31/2023N/A-36-33-29N/A
12/31/20221-41-28-24N/A
9/30/20221-39-28-24N/A
6/30/20221-39-28-24N/A
3/31/20223-35-23-23N/A
12/31/20218-21-26-26N/A
9/30/202110-18-18-18N/A
6/30/202110-15-15-15N/A
3/31/20218-15-14-14N/A
12/31/20202-17-10-10N/A
9/30/2020N/A-21-18-18N/A
6/30/2020N/A-28-18-18N/A
3/31/2020N/A-27-19-19N/A
12/31/2019N/A-28-18-18N/A
9/30/2019N/A-34-18-18N/A
6/30/2019N/A-32-28-28N/A
3/31/2019N/A-36-30-30N/A
12/31/2018N/A-41-30-30N/A
9/30/2018N/A-37-28-28N/A
6/30/2018N/A-32-16-16N/A
3/31/2018N/A-30N/A-13N/A
12/31/2017N/A-24N/A-11N/A
9/30/2017N/A-21N/A-14N/A
6/30/2017N/A-23N/A-16N/A
3/31/2017N/A-20N/A-14N/A
12/31/2016N/A-18N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RXK3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RXK3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RXK3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RXK3 is forecast to have no revenue next year.

High Growth Revenue: RXK3 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RXK3's Return on Equity is forecast to be high in 3 years time


Discover growth companies